1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cervical Cancer Partnering 2010-2015

Cervical Cancer Partnering 2010-2015

  • March 2015
  • -
  • Currentpartnering
  • -
  • 150 pages

The Cervical Cancer Partnering 2010-2015 report provides understanding and access to the cervical cancer partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in cervical cancer partnering deals
Top cervical cancer deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type

The Cervical Cancer Partnering 2010-2015 provides understanding and access to the cervical cancer partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of cervical cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors cervical cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 50 links to online copies of actual cervical cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of cervical cancer partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.

Chapter 3 provides an overview of the average deal terms since 2010. The chapter includes deals with a stage of development announced by headline value, upfront value, milestone value and royalty rate. Numerous tables outline financial trends.

Chapter 4 provides an overview of the most active dealmakers, top dealmakers by value, active big pharma and big biotech dealmakers including contract documents where available.

Chapter 5 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of brain cancer technologies and products.

Report scope

Cervical Cancer Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to cervical cancer trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

Trends in cervical cancer dealmaking in the biopharma industry since 2010
Access to summary headline, upfront, milestone and royalty data
The leading cervical cancer deals by value since 2010

In Cervical Cancer Partnering 2010-2015, the available deals are listed by:

Headline value
Upfront payment value
Royalty rate value
Company A-Z
Industry sector
Stage of development at signing
Deal component type
Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Table Of Contents

Cervical Cancer Partnering 2010-2015
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cervical cancer partnering

2.1. Introduction
2.2. Cervical cancer partnering over the years
2.3. Cervical cancer partnering by deal type
2.4. Cervical cancer partnering industry sector
2.5. Cervical cancer partnering by stage of development
2.6. Cervical cancer partnering by technology type

Chapter 3 - Average deal terms for cervical cancer

3.1 Introduction
3.2 Average deal terms for Cervical cancer
3.3 Cervical cancer headline values with median calculation
3.4 Cervical cancer upfront values with median calculation
3.5 Cervical cancer milestone values with median calculation
3.6 Cervical cancer royalty rates with median calculation

Chapter 4 - Active cervical cancer dealmakers

4.1. Introduction
4.2 Most active cervical cancer dealmakers
4.3. Top Cervical cancer deals by value
4.4 Big pharma deal activity
4.5 Big biotech deal activity

Chapter 5 - Cervical cancer dealmaking directory

5.1. Introduction
5.2. Company A-Z
5.3. By deal type
5.4. By industry sector
5.5. By stage of development
5.6. By technology type

Chapter 6 - Partnering resource center

6.1. Online partnering
6.2. Partnering events
6.3. Further reading on dealmaking

Appendices

Appendix 1 - Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form - Reports
Order Form - Subscription Access Products

Table of figures

Figure 1: Cervical cancer partnering since 2010
Figure 2: Cervical cancer dealmaking activity- 2010 to 2015
Figure 3: Cervical cancer partnering by deal type since 2010
Figure 4: Cervical cancer partnering by industry sector since 2010
Figure 5: Cervical cancer partnering by stage of development since 2010
Figure 6: Cervical cancer partnering by technology type since 2010
Figure 7: Cervical cancer deals with a headline value
Figure 8: Cervical cancer deals with upfront payment values
Figure 9: Cervical cancer deals with milestone payments
Figure 10: Cervical cancer deals with royalty rates, %
Figure 11: Top Cervical cancer deals by value since 2010
Figure 12: Big pharma - top 50 - Cervical cancer deals 2010 to 2015
Figure 13: Big pharma cervical cancer deal frequency - 2010 to 2015
Figure 14: Big biotech - top 50 - Cervical cancer deals 2010 to 2015
Figure 15: Big biotech cervical cancer deal frequency - 2010 to 2015
Figure 16: Online partnering resources
Figure 17: Forthcoming partnering events
Figure 18: Deal type definitions

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Women’s Health Diagnostics Market by Application End User - Forecast to 2021

Women’s Health Diagnostics Market by Application End User - Forecast to 2021

  • $ 5650
  • Industry report
  • November 2016
  • by MarketsandMarkets

Women's Health Diagnostics Market by Application (Prenatal Testing, Down Syndrome, HPV, Fertility Test, Pregnancy Test, Urinary Tract Infections, Osteoporosis, Breast, Cervical and Ovarian Cancer Test) ...

Epiomic Epidemiology Series: Cervical Cancer Forecast in 22 Major Markets 2016 - 2026

Epiomic Epidemiology Series: Cervical Cancer Forecast in 22 Major Markets 2016 - 2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Cervical Cancer in 22 Major Markets Cervical cancer (ICD-10 code C53, cervix uteri) is a type of cancer that occurs in the cells of ...

Cervical Cancer Diagnostic Market Analysis By Test Type and Segment Forecasts to 2024

Cervical Cancer Diagnostic Market Analysis By Test Type and Segment Forecasts to 2024

  • $ 4950
  • Industry report
  • September 2016
  • by Grand View Research

The global cervical cancer diagnostic market was valued at USD 7 billion in 2015 and is expected to reach a value of USD 12 billion by 2024, according to a new report by Grand View Research, Inc. The key ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the UK

  • November 2016
    10 pages
  • Cancer  

  • United Kingdom  

View report >

Cervical Cancer Statistics

  • November 2016
    6 pages
  • Cervical Cancer  

    Vaccine  

    HPV Vaccine  

View report >

Cancer Statistics in the US

  • November 2016
    74 pages
  • Cancer  

  • United States  

View report >

Cancer Statistics

29 days ago

Related Market Segments :

Cervical Cancer

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.